Fintel reports that on September 5, 2023, JP Morgan maintained coverage of Akero Therapeutics (NASDAQ:AKRO) with a Overweight recommendation.Fintel reports that on September 5, 2023, JP Morgan maintained coverage of Akero Therapeutics (NASDAQ:AKRO) with a Overweight recommendation.
